Wellbeing Technology Assessment

1785 days ago, 683 views
PowerPoint PPT Presentation
Layout. Apportioning feeInternational BenchmarkingDraft Guidelines on the Submission of Economic AnalysisHealth Technology. Apportioning FEE. . Apportioning definition. 3 activities:Evaluation of script (guidance for OTC)Preparation of medicineAdvising patientExcludes:Compounding

Presentation Transcript

Slide 1

Wellbeing Technology Assessment Anban Pillay Acting Cluster Manager: Health Economics and Financing National Department of Health

Slide 2

Outline Dispensing charge International Benchmarking Draft Guidelines on the Submission of Economic Analysis Health Technology

Slide 3


Slide 4

Dispensing definition 3 exercises: Evaluation of script (guidance for OTC) Preparation of prescription Advising persistent Excludes: Compounding & admixing Delivery to quiet – particular, straightforward expense so patient can choose ( however does incorporate transport for crisis stock get to)

Slide 5

Principles Appropriate: Affordability and accessibility Viability: take care of expenses and reasonable rate of return (ROI) yet fitting volume (2,300 pm – drug specialist & collaborator) Closely rough an expert charge (most level rate) Encourage suitable motivators

Slide 6

Costing "Standardizing" display/zero-based gauge: scratch witness interviews, provider information 100% dispensary just costs (ice chest, and so forth.) 43% of space related (lease, power, and so on.) 70% different costs (stationery, and so on.) ROI of 10% on R450,000 (NHRPL point of reference) Cross-check with partner information R21-R22 VAT select

Slide 7

Estimating pay Estimate normal apportioning expense per thing – focus of costs + ROI SEP groups basic: Medical plans (90% of market) PSSA 'uber test' of drug stores Key issue: 95% of volume have SEP< R250

Slide 8

Recommended administering expense (VAT restrictive)

Slide 9

Average administering expense

Slide 10

Response after Promulgation of the Dispensing charge PSSA kept the execution of the expense MoH concurred gave that case is heard on earnest premise Exchange of papers between gatherings No date for court hearing

Slide 11

International Benchmarking

Slide 12

Process Invitation for recommendations on strategy Review of proposition Finalization of draft approach Publication for input Review of remarks Finalization of technique Implementation

Slide 13

Methodology Originator medications Generic Medicines

Slide 14

Combination Drugs Assessed in view of individual dynamic fixings TOTAL SEP = SUM OF COMPONENTS Dual procedure may apply

Slide 15

Different Trade Names Same Manufacturer Same actives Different exchange names Lowest SEP material

Slide 16

OTHER ISSUES "Impermanent" value decreases Pharmacy organization expense – improper Price changes and new item value presentations

Slide 17

Risk Sharing Proposals Pharmaceutical industry has thought of a scope of hazard sharing Proposals are identified with uncommon ailments where treatment is costly Usually constrained clinical confirmation to bolster utilization of the treatment Pricing board of trustees needs to give favor such proposition

Slide 18

Billing for Anesthetic gasses Manufacturers of gasses offer gasses in ml or mg Patients can't be charged for gasses in minutes Low stream conveyance accessible at private doctor's facilities Hospital bunches have been educated that their charging frameworks are unseemly

Slide 19

Draft Guidelines on the Submission of Economic Analysis

Slide 20

Key Areas Details of the proposed medication and its proposed utilize Data from similar randomized trials Modeled monetary assessment for fundamental sign Estimated degree of utilization and money related ramifications

Slide 21


Slide 22

Health Technology Assessment Quality Safety Efficacy Expenses Cost Benefit/Cost Effectiveness

Slide 23

Health Technology - Quality Assessment of the nature of wellbeing innovation Components of the gadgets Stds for the segment/s Assessment of every segment Assessment of all segments working as unit

Slide 24

Health Technology - Safety Assessment of the security of wellbeing innovation Safety to the patient Safety to the administrator/overseer Safety of the earth

Slide 25

Health Technology - adequacy Assessment of the adequacy of wellbeing innovation Does the wellbeing innovation do what is asserted? How well does it do this? How well does the innovation function contrast with the innovation that we as of now have?

Slide 26

Health Technology cost viability/money saving advantage Comparative adequacy of the new innovation contrasted with innovation presently accessible Comparative cost of the new innovation contrasted with innovation as of now accessible

Slide 27

Clinical and Health Technology Guidelines Is there a requirement for partitioned open and private division rules

Slide 28

GUIDELINES Both clinical rules and wellbeing innovation appraisal rules depend on confirmation based solution. Sensible for the business to receive the general population division rules.

Slide 29